2014
Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal Of Clinical Oncology 2014, 32: 2318-2327. PMID: 24934786, PMCID: PMC4105485, DOI: 10.1200/jco.2013.51.7367.Peer-Reviewed Original ResearchConceptsAdjuvant hormonal therapyHormonal therapyBreast cancerOlder womenInfluence of frailtyCovariate adjustmentRisk of discontinuationNonmetastatic breast cancerBreast cancer ageProportional hazards modelIIB diseaseEarly discontinuationMost patientsOlder patientsProspective cohortBaseline frailtyCancer ageHigher oddsDiscontinuationHazards modelMost womenPsychosocial dataNoninitiationTherapyLogistic regression
2013
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.
Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Annals Of Internal Medicine 2013, 159: 373-81. PMID: 24042365, PMCID: PMC3968260, DOI: 10.7326/0003-4819-159-6-201309170-00003.Peer-Reviewed Original ResearchConceptsContralateral prophylactic mastectomyContralateral breast cancerBreast cancerCross-sectional surveyYoung womenProphylactic mastectomyBilateral breast cancerBreast cancer worryAge 40 yearsCommunity medical centerBRCA2 mutation carriersSusan G. KomenBilateral mastectomyUnaffected breastCancer worryMedical CenterMutation carriersMost womenCancerEvidence-based decisionsMastectomyRecall biasWomenRiskActual risk
2009
Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ
Ligibel JA, Partridge A, Giobbie-Hurder A, Golshan M, Emmons K, Winer EP. Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ. Annals Of Surgical Oncology 2009, 16: 106-112. PMID: 18953612, PMCID: PMC5842912, DOI: 10.1245/s10434-008-0174-x.Peer-Reviewed Original ResearchConceptsPhysical activityDuctal carcinomaTreatment-related variablesLongitudinal cohort studyStrenuous physical activityBreast cancer riskLogistic regression modelingPhysical activity behaviorType of exerciseTamoxifen useCohort studyBilateral mastectomyEpidemiological evidenceSitu cancerReconstructive surgeryCancer riskDepressive symptomsExercise levelsMost womenExercise frequencyHealth outcomesActivity behaviorWomenExercise behaviorNonsignificant variables
2001
New Combinations with Herceptin® in Metastatic Breast Cancer
Winer E, Burstein H. New Combinations with Herceptin® in Metastatic Breast Cancer. Oncology 2001, 61: 50-57. PMID: 11694788, DOI: 10.1159/000055402.Peer-Reviewed Original ResearchMeSH KeywordsAnastrozoleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclophosphamideDeoxycytidineDoxorubicinDrug InteractionsDrug SynergismEpirubicinFemaleFluorouracilGemcitabineHeart DiseasesHematologic DiseasesHumansMethotrexateNeoplasm MetastasisNitrilesOrganoplatinum CompoundsPaclitaxelTamoxifenThiotepaTrastuzumabTreatment OutcomeTriazolesVinblastineVinorelbineConceptsMetastatic breast cancerBreast cancerHormonal agentsSide effectsHER2-positive metastatic breast cancerPivotal phase III trialsHER2-positive breast cancerSingle-agent vinorelbineCombination of trastuzumabPhase II trialPhase III trialsMajor side effectsPossible side effectsHormonal therapyII trialIII trialsCombination regimensPreclinical dataClinical trialsMost womenBetter outcomesTrastuzumabCancerTrialsLiposomal formulation